CHO/Human B7-H3 (4Ig) Stable Cell Line Development Service
描述（Description）
The CHO/Human B7-H3 (4Ig) Stable Cell Line was engineered to express the receptor full length human B7-H3 (4Ig) (Gene ID: 80381), used to mimic cancer target cells. Surface expression of human B7-H3 (4Ig) was confirmed by flow cytometry.
應(yīng)用說(shuō)明（Application）
Useful for cell-based B7-H3 (4Ig) binding assay
生長(zhǎng)特性（Growth Properties）
Adherent
篩選標(biāo)記（Selection Marker）
Puromycin (2 μg/mL)
培養(yǎng)基（Culture Medium）
F-12K + 10% FBS
凍存液（Freeze Medium）
Serum-free cell cryopreservation medium
裝量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存儲(chǔ)（Storage）
Frozen in liquid nitrogen.
支原體檢測(cè)（Mycoplasma Testing）
Negative
無(wú)菌檢測(cè)（Sterility Testing）
Negative
使用說(shuō)明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
B7 homolog 3 (B7-H3), a member of the immunoglobulin superfamily, is also known CD276, which contains two Ig-like C2-type (immunoglobulin-like) domains and two Ig-like V-type (immunoglobulin-like) domains. B7-H3 may participate in the regulation of T-cell-mediated immune response. B7-H3 also plays a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. Furthermore, B7-H3 is involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. It could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關(guān)鍵字： B7-H3穩(wěn)定細(xì)胞系;B7-H3細(xì)胞系;B7-H3細(xì)胞株;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶(hù)超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。